Over the past 24 years, HealthCare Ventures has raised $1.6 billion in eight funds. The firm's investment strategy, which is focused primarily on early-stage companies, supports those with a broad array of technology platforms and late-stage products or novel innovations. HCV's main areas of investment include target-focused cancer, infectious disease, cardiovascular disease, CNS disorders, immunomodulation and immunotherapy, novel manufacturing technologies, and novel lab scale instruments and reagents.